Histone Deacetylase 3 - Pipeline Review, H2 2019
Summary
According to the recently published report 'Histone Deacetylase 3 - Pipeline Review, H2 2019'; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.
The report 'Histone Deacetylase 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Non-Small Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Epithelial Ovarian Cancer, Glioblastoma Multiforme (GBM), Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Mycosis Fungoides, Neuroblastoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Disorders, Central Nervous System (CNS) Tumor, CNS Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Fallopian Tube Cancer, Gliosarcoma, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Liver Fibrosis, Lung Adenocarcinoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL) and Renal Cell Carcinoma.
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4D Pharma Plc
4SC AG
Chipscreen Biosciences Ltd
Curis Inc
IRBM Science Park SpA
Kdac Therapeutics Inc
Medivir AB
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
OnKure Inc
Shuttle Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles
domatinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRx-1299 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKI-422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC2 and HDAC3 for Burkitt Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Dec 06, 2019: Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
Dec 02, 2019: Chidamide gets approval in China for breast cancer indication
Nov 06, 2019: Curis abstracts for Fimepinostat accepted for presentation at the 61st Annual Meeting of the American Society of Hematology
Oct 21, 2019: 4SC: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma
Oct 16, 2019: 4SC and Netherlands Cancer Institute Collaborate on clinical evaluation of domatinostat in the neoadjuvant setting in melanoma
Sep 23, 2019: 4D pharma: Publication of data on neurodegenerative disease programme MRx0029
Aug 06, 2019: Curis provides update on development of Fimepinostat
Jul 25, 2019: Positive safety review of phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
Jul 25, 2019: 4D pharma provides update on MRx1299
Jul 11, 2019: 4SC announces Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma
May 13, 2019: Positive data from the remetinostat Phase II study in basal cell carcinoma presented at SID Annual meeting
May 13, 2019: 4D pharma presents on its Parkinson's Disease drug candidate MRx0029 at Neuro4D Conference, Frankfurt, Germany
May 07, 2019: Data From the Remetinostat Phase II Study in Basal Cell Carcinoma Patients to be Presented at the 2019 SID Annual Meeting
May 02, 2019: 4D to present preclinical data on MRx 0029 at Neuro4D conference
Apr 08, 2019: 4SC: Domatinostats mode of action in Merkel cell carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by 4D Pharma Plc, H2 2019
Pipeline by 4SC AG, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Curis Inc, H2 2019
Pipeline by IRBM Science Park SpA, H2 2019
Pipeline by Kdac Therapeutics Inc, H2 2019
Pipeline by Medivir AB, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
Pipeline by OnKure Inc, H2 2019
Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
Pipeline by Syndax Pharmaceuticals Inc, H2 2019
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
List of Figures
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
4D Pharma Plc
4SC AG
Chipscreen Biosciences Ltd
Curis Inc
IRBM Science Park SpA
Kdac Therapeutics Inc
Medivir AB
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
OnKure Inc
Shuttle Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
*If Applicable.